SteelPeak Wealth LLC Acquires 20,118 Shares of Amgen Inc. $AMGN

SteelPeak Wealth LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 17.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 135,846 shares of the medical research company’s stock after buying an additional 20,118 shares during the period. Amgen comprises 1.5% of SteelPeak Wealth LLC’s portfolio, making the stock its 13th largest holding. SteelPeak Wealth LLC’s holdings in Amgen were worth $47,797,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Anfield Capital Management LLC grew its position in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Dogwood Wealth Management LLC increased its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Board of the Pension Protection Fund bought a new position in Amgen in the 4th quarter worth $26,000. Tower View Wealth Management LLC raised its holdings in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the period. Finally, Manning & Napier Advisors LLC lifted its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 3.7%

Shares of AMGN opened at $371.58 on Friday. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01. The stock has a market capitalization of $200.55 billion, a price-to-earnings ratio of 25.86, a price-to-earnings-growth ratio of 3.63 and a beta of 0.41. Amgen Inc. has a 1 year low of $269.77 and a 1 year high of $391.29. The business’s 50 day simple moving average is $347.00 and its 200-day simple moving average is $350.27.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion during the quarter, compared to analyst estimates of $8.58 billion. During the same period last year, the firm posted $4.90 earnings per share. Amgen’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts expect that Amgen Inc. will post 22.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AMGN. Canaccord Genuity Group started coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Truist Financial raised their price objective on Amgen from $327.00 to $340.00 and gave the stock a “hold” rating in a research note on Tuesday, July 7th. Royal Bank Of Canada reiterated a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Daiwa Securities Group reduced their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a report on Wednesday, May 13th. Finally, Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $356.62.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 0.85% of the stock is owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.